Obseva

  • TickerOBSN
  • ISINCH0346177709
  • ExchangeSix Swiss Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountrySwitzerland
Liana Moussatos ... (+2)
  • Liana Moussatos
  • Andreas Argyrides
OBSN OBSEVA (Health Care)

Slight improvement for OBSEVA, which now displays a rating of Neutral ...

The independent financial analyst theScreener just requalified the general evaluation of OBSEVA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title loses a star(s) and now shows 1 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky moving forward. theScreener believes that the improved risk assessment represents a slight improvement for the title, which merits an overall rating upgrade to Neutral - even if under pressure. As of the analysis date July 6, 2021, the closing price was USD 2.87 and its target p...

Liana Moussatos ... (+2)
  • Liana Moussatos
  • Andreas Argyrides
 PRESS RELEASE
OBSN OBSEVA (Health Care)

ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (li...

ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting -Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo transfer -   GENEVA, Switzerland and BOSTON – June 30, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced clinical da...

 PRESS RELEASE
OBSN OBSEVA (Health Care)

ObsEva To Present Data on Two Clinical Development Programs at ESHRE V...

ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting   - Data from Phase 3 study of Yselty® (linzagolix) for the treatment of uterine fibroids to be discussed in an oral presentation; Top-line data from pilot study of Yselty for the treatment of severe adenomyosis to be presented in an ePoster - -Data from IMPLANT 1 Phase 2 study of nolasiban for uterine contractility of IVF patients prior to embryo transfer to be presented in an ePoster -   GENEVA, Switzerland and BOSTON – June 24, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OB...

Liana Moussatos ... (+2)
  • Liana Moussatos
  • Andreas Argyrides
OBSN OBSEVA (Health Care)

Slight improvement for OBSEVA, which now displays a rating of Neutral ...

The independent financial analyst theScreener just requalified the general evaluation of OBSEVA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title loses a star(s) and now shows 1 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky moving forward. theScreener believes that the improved risk assessment represents a slight improvement for the title, which merits an overall rating upgrade to Neutral - even if under pressure. As of the analysis date July 6, 2021, the closing price was USD 2.87 and its target p...

Liana Moussatos ... (+2)
  • Liana Moussatos
  • Andreas Argyrides
 PRESS RELEASE
OBSN OBSEVA (Health Care)

ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (li...

ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting -Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo transfer -   GENEVA, Switzerland and BOSTON – June 30, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced clinical da...

 PRESS RELEASE
OBSN OBSEVA (Health Care)

ObsEva To Present Data on Two Clinical Development Programs at ESHRE V...

ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting   - Data from Phase 3 study of Yselty® (linzagolix) for the treatment of uterine fibroids to be discussed in an oral presentation; Top-line data from pilot study of Yselty for the treatment of severe adenomyosis to be presented in an ePoster - -Data from IMPLANT 1 Phase 2 study of nolasiban for uterine contractility of IVF patients prior to embryo transfer to be presented in an ePoster -   GENEVA, Switzerland and BOSTON – June 24, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OB...

Liana Moussatos ... (+2)
  • Liana Moussatos
  • Andreas Argyrides
OBSN OBSEVA (Health Care)

Slight improvement for OBSEVA, which now displays a rating of Neutral ...

The independent financial analyst theScreener just requalified the general evaluation of OBSEVA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title loses a star(s) and now shows 1 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky moving forward. theScreener believes that the improved risk assessment represents a slight improvement for the title, which merits an overall rating upgrade to Neutral - even if under pressure. As of the analysis date July 6, 2021, the closing price was USD 2.87 and its target p...

Liana Moussatos ... (+2)
  • Liana Moussatos
  • Andreas Argyrides
 PRESS RELEASE
OBSN OBSEVA (Health Care)

ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (li...

ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting -Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo transfer -   GENEVA, Switzerland and BOSTON – June 30, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced clinical da...

 PRESS RELEASE
OBSN OBSEVA (Health Care)

ObsEva To Present Data on Two Clinical Development Programs at ESHRE V...

ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting   - Data from Phase 3 study of Yselty® (linzagolix) for the treatment of uterine fibroids to be discussed in an oral presentation; Top-line data from pilot study of Yselty for the treatment of severe adenomyosis to be presented in an ePoster - -Data from IMPLANT 1 Phase 2 study of nolasiban for uterine contractility of IVF patients prior to embryo transfer to be presented in an ePoster -   GENEVA, Switzerland and BOSTON – June 24, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OB...

Liana Moussatos ... (+2)
  • Liana Moussatos
  • Andreas Argyrides
OBSN OBSEVA (Health Care)

Slight improvement for OBSEVA, which now displays a rating of Neutral ...

The independent financial analyst theScreener just requalified the general evaluation of OBSEVA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title loses a star(s) and now shows 1 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky moving forward. theScreener believes that the improved risk assessment represents a slight improvement for the title, which merits an overall rating upgrade to Neutral - even if under pressure. As of the analysis date July 6, 2021, the closing price was USD 2.87 and its target p...

Liana Moussatos ... (+2)
  • Liana Moussatos
  • Andreas Argyrides
 PRESS RELEASE
OBSN OBSEVA (Health Care)

ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (li...

ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting -Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo transfer -   GENEVA, Switzerland and BOSTON – June 30, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced clinical da...

 PRESS RELEASE
OBSN OBSEVA (Health Care)

ObsEva To Present Data on Two Clinical Development Programs at ESHRE V...

ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting   - Data from Phase 3 study of Yselty® (linzagolix) for the treatment of uterine fibroids to be discussed in an oral presentation; Top-line data from pilot study of Yselty for the treatment of severe adenomyosis to be presented in an ePoster - -Data from IMPLANT 1 Phase 2 study of nolasiban for uterine contractility of IVF patients prior to embryo transfer to be presented in an ePoster -   GENEVA, Switzerland and BOSTON – June 24, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OB...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch